GlassScriptPhysician profile
John S Belle
NPI 1508000621
$1,293.53
in general payments reported to CMS, 2019-2025
17 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.06 · 2020: $20.87 · 2021: $13.84 · 2022: $160 · 2023: $288 · 2024: $372 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036 · Education: $51.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.31 |
| Education | $51.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $313.99 | 2023-2025 | Xtandi, Xospata |
| Astrazeneca Pharmaceuticals LP | $179.06 | 2022-2024 | Enhertu |
| Gilead Sciences, INC. | $134.65 | 2021-2024 | Trodelvy |
| Karyopharm Therapeutics INC. | $113.86 | 2023 | Xpovio |
| Glaxosmithkline, LLC. | $98.61 | 2024-2025 | Ojjaara, Blenrep |
| Celgene Corporation | $83.99 | 2023-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $74.52 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Abbvie INC. | $69.98 | 2024-2025 | |
| Janssen Biotech, INC. | $44.50 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Boston Scientific Corporation | $31.93 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.77 | 2024 | Iclusig |
| Novartis Pharmaceuticals Corporation | $25.08 | 2025 | |
| Daiichi Sankyo INC. | $22.19 | 2025 | Datroway |
| Kite Pharma, INC. | $21.14 | 2023 | |
| Array Biopharma INC | $19.48 | 2024 | Braftovi, Tukysa, Mektovi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $17.82 | 2023 | Jakafi |
| G1 Therapeutics, INC. | $14.96 | 2023 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Belle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.